Physician profile
David E Roffwarg
NPI 1063736833
$9,154.94
in general payments reported to CMS, 2019-2025
34 companies · $1,712 in 2025
The $1,712 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,801 · 2020: $434 · 2021: $153 · 2022: $851 · 2023: $1,244 · 2024: $1,961 · 2025: $1,712.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,837 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,836.54 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,886.95 | 2019-2025 | Rinvoq, Skyrizi |
| Galderma Laboratories, L.P. | $1,504.03 | 2019-2025 | Nemluvio |
| Sun Pharmaceutical Industries INC. | $777.07 | 2019-2025 | Blu-U, Odomzo, Ilumya |
| Genzyme Corporation | $763.60 | 2019-2025 | |
| Janssen Biotech, INC. | $692.98 | 2019-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $539.29 | 2019-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $356.58 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $347.19 | 2022-2024 | Sotyktu |
| Leo Pharma INC. | $308.22 | 2019-2025 | Adbry, Anzupgo |
| Ucb, INC. | $303.02 | 2019-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $284.37 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Incyte Corporation | $189.89 | 2024-2025 | Opzelura |
| Amgen INC. | $177.35 | 2019-2025 | Otezla, Otezla |
| Pfizer INC. | $157.10 | 2019-2024 | |
| Convatec INC. | $124.63 | 2023-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $101.75 | 2023-2025 | Affinity, Puraply Wound Matrix, Puraply |
| Mayne Pharma Commercial LLC | $90.50 | 2025 | |
| Biofrontera INC. | $73.15 | 2020-2023 | Ameluz, Xepi, Bf-Rhodoled |
| Prugen, INC. Pharmaceuticals | $64.92 | 2020 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $52.68 | 2019 | |
| Surgenex LLC | $51.68 | 2025 | Renograft, Ardeograft, Surmatrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.97 | 2022 | |
| Almirall LLC | $43.38 | 2022-2024 | Seysara |
| Arcutis Biotherapeutics, INC. | $31.31 | 2025 | Zoryve |
| Verrica Pharmaceuticals INC. | $25.96 | 2024 | Ycanth |
| Alnylam Pharmaceuticals INC. | $25.79 | 2024 | Givlaari |
| Triad Life Sciences INC. | $22.47 | 2022 | |
| Integra Lifesciences Corporation | $22.37 | 2023 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Ets Wound Care LLC | $19.61 | 2025 | Mirragen Advanced Wound Matrix |
| Epi Health, LLC | $15.14 | 2021 | |
| Smith+Nephew, INC. | $14.62 | 2025 | Pico |
| Medline Industries Lp | $14.19 | 2019 | |
| Vyne Pharmaceuticals INC. | $14.18 | 2020 | |
| Organon LLC | $12.00 | 2023 | Hadlima |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Roffwarg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.